A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVΔG-ZEBOV-GP-primed volunteers (Boost-EBOV)

Key Points

• Finds that the Ebolavirus DNA vaccine candidate INO-4201 shows promise in boosting immune response.
• Key evidence includes promising immune responses observed in volunteers primed with rVSVΔG-ZEBOV-GP.
• Placebo-controlled randomized clinical trial protocol assessing vaccination strategy with electroporation.
• Highlights the importance of exploring innovative boost vaccination methods, with potential implications for ebola prevention.